Antigens, Viral
These antigens play a key role in viral infection and disease pathogenesis.
Identifying and characterizing viral antigens is crucial for developing effective vaccines, diagnostics, and therapeutic interventinos.
PubCompare.ai's AI-driven platform can help researchers optimize their viral antigen research by effortleslly locating the best protocols from literature, pre-prints, and patents using intelligent comparison tools.
Leverage cutting-edge AI to pinpoint the optimal solutions and products for your needs, and take your viral antigen research to new heights.
Most cited protocols related to «Antigens, Viral»
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Most recents protocols related to «Antigens, Viral»
Example 3
Investigation of Virus Infectivity as a Factor that Determines Plaque Size.
With the revelation that plaque formation is strongly influenced by the immunogenicity of the virus, the possibility that infectivity of the virus could be another factor that determines plaque sizes was investigated. The uptake of viruses into cells in vitro was determined by measuring the amounts of specific viral RNA sequences through real-time PCR.
To measure total viral RNA, total cellular RNA was extracted using the RNEasy Mini kit (Qiagen), and complementary DNA synthesized using the iScript cDNA Synthesis kit (Bio-Rad). To measure total viral RNA, quantitative real-time PCR was done using a primer pair targeting a highly conserved region of the 3′ UTR common to all four serotypes of dengue; inter-sample normalization was done using GAPDH as a control. Primer sequences are listed in Table 5. Pronase (Roche) was used at a concentration of 1 mg/mL and incubated with infected cells for five minutes on ice, before washing with ice cold PBS. Total cellular RNA was then extracted from the cell pellets in the manner described above.
The proportion of infected cells was assessed by flow cytometry. Cells were fixed and permeabilised with 3% paraformaldehyde and 0.1% saponin, respectively. DENV envelope (E) protein was stained with mouse monoclonal 4G2 antibody (ATCC) and AlexaFluor488 anti-mouse secondary antibody. Flow cytometry analysis was done on a BD FACS Canto II (BD Bioscience).
Unexpectedly, despite DENV-2 PDK53 inducing stronger antiviral immune responses, it had higher rates of uptake by HuH-7 cells compared to DENV-2 16681 (
Results above demonstrate that the DENV-2 PDK53 and DENV-3 PGMK30 are polarized in their properties that influence plaque morphologies. While both attenuated strains were selected for their formation of smaller plaques compared to their parental strains, the factors leading to this outcome are different between the two.
Accordingly, this study has demonstrated that successfully attenuated vaccines, as exemplified by DENV-2 PDK53 in this study, form smaller plaques due to induction of strong innate immune responses, which is triggered by fast viral uptake and spread of infection. In contrast, DENV-3 PGMK30 form smaller plaques due to its slower uptake and growth in host cells, which inadvertently causes lower up-regulation of the innate immune response.
Based on the results presented in the foregoing Examples, the present invention provides a new strategy to prepare a LAV, which expedites the production process and ensures the generation of effectively attenuated viruses fit for vaccine use.
Example 14
In contrast to the previous experimental infection using specific pathogen-free Beagles (Crawford et al., 2005), the virus-inoculated mongrel dogs had pneumonia as evidenced by gross and histological analyses of the lungs from days 1 to 6 p.i. In addition to pneumonia, the dogs had rhinitis, tracheitis, bronchitis, and bronchiolitis similar to that described in naturally infected dogs (Crawford et al., 2005). There was epithelial necrosis and erosion of the lining of the airways and bronchial glands with neutrophil and macrophage infiltration of the submucosal tissues (
Example 6
The assay was made for determining the maximum dilution of the monoclonal antibodies RSV anti-P from the hybridomas 2E6/D2 and 6H5/H1, which allow the detection of the viral antigen using ELISA. For this, the same indirect ELISA technique was used of the example 6. The well was activated with 50 ng of the purified antigen and the anti-P antibodies 2E6/D2 or 6H5/H1 were used in dilutions 1:2, starting from the concentration of work (3.4 μg/ml) to the dilution 11 in PBS/FBS 10%. In
The negative control included on this assay, correspond to a well which does not contain sample (protein P), it was blocked with PBS/FBS 10%, primary antibody was not added (anti-P 2E6/D2 or anti-P 6H5/H1) and it contains only the mouse anti-IgG antibody conjugated with HRP.
Serologic testing was performed on acute-phase samples using two different methods. First, anti-DENV IgG and IgM were analyzed using commercial ELISA kits [Dengue ELISA IgG (G1018) and Dengue ELISA IgM Capture (M1018), Vircell Microbiologists, Granada, Spain] according to manufacturer recommendations (interpretation: IgM or IgG index >11 positive, 9–11 indeterminate, <9 negative). Second, a 5μL aliquot of serum from 139 participants with sufficient sample was tested in the pGOLD assay (Nirmidas Biotech, Inc, Palo Alto, CA), which is a multiplex serological assay for IgM and IgG against DENV (DENV-2 whole virus antigen) and ZIKV (NS1 antigen). The pGOLD assay was performed as previously described [59 (link), 63 (link)]. In each well of the pGOLD slide, antigens are spotted in triplicate, and average signals are used during analysis. For IgG, the negative control signal was subtracted from the sample signal, and the difference was divided by the average signal of four IgG control spots included in each well. For IgM, a similar calculation was performed using the signal from a known anti-DENV IgM positive control sample included on each run. A positive threshold ratio of 0.1 was established for each isotype, which was ≥ 3 standard deviations above the mean of the negative control.
Chymase and LBP levels were determined using commercial ELISA kits (G-Biosciences, St. Louis, MO, USA), following the manufacturer’s instructions. Complete blood counts and chemistries were performed at the clinical site at the discretion of the care team, and results were included if the sample was obtained within ±1 day of enrollment.
Similarly, the NNV-specific IgT or IgM level was determined by indirect ELISA. Purified RGNNV viral antigen was coated onto microtiter well ELISA plates and incubated overnight at 4°C. After washing and blocking with 3% BSA, 100 µl of gill or intestine mucosal wash samples were added and plates were incubated for 1 h at 37°C. Plates were washed three times and a 100 µl aliquot containing 1:200 dilutions of rabbit anti-CH2-CH4 IgT or 1:33 dilutions of anti-ASB IgM monoclonal antibody (Aquatic Diagnostics Ltd., Stirling, UK) was added and incubated for 1 h at 37°C. The color development was then visualized by adding goat anti-rabbit HRP-conjugated antibody or rabbit anti-mouse IgG conjugated to HRP (Dako Cytomation, Denmark) to the respective wells and followed by the addition of 3,3’,5,5’-tetramethylbenzidine (Sigma). The absorbance was measured at 450 nm using a microwell plate reader.
Top products related to «Antigens, Viral»
More about "Antigens, Viral"
These antigenic proteins play a crucial role in the process of viral infection and disease pathogenesis.
Identifying and characterizing these viral antigens is essential for the development of effective vaccines, diagnostic tools, and therapeutic interventions.
The study of viral antigens encompasses a wide range of subtopics, including the identification and characterization of specific viral epitopes, the development of monoclonal antibodies (e.g., Anti-M2 monoclonal antibody (14C2)), the use of techniques like DAPI staining and the QIAamp Viral RNA Mini Kit for sample preparation, and the utilization of various reagents such as bovine serum albumin (BSA), fetal bovine serum (FBS), FITC-conjugated rabbit anti-pig antibody, streptomycin, Triton X-100, DMSO, and primary goat polyclonal antibodies.
Researchers can leverage the power of AI-driven platforms like PubCompare.ai to optimize their viral antigen research.
These cutting-edge tools can effortlessly locate the best protocols from literature, preprints, and patents using intelligent comparison features, helping researchers identify the optimal solutions and products for their specific needs.
By harnessing the power of AI, researchers can take their viral antigen research to new heights and accelerate the development of effective vaccines, diagnostics, and therapies.